First-in-Human Dose Selection and Pharmacokinetics, Safety, Tolerability, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase (P10-2.007)

To present the approach for selection of first-in-human (FIH) doses and the results of a phase 1, FIH, double-blinded, placebo-controlled study (NCT05670704) of single ascending doses (SAD) and multiple ascending doses (MAD) of ARGX-119 in healthy participants.

Authors

Tonke Van Bragt
Samir Patel
Roeland Vanhauwaert (ORCID: https://orcid.org/0000-0003-0829-6128)
Christa Kneip (ORCID: https://orcid.org/0000-0003-0685-1810)
Sofie Priem
Rebecca A. Shilling (ORCID: https://orcid.org/0000-0002-6326-2150)
Cristina Vaghi
Peter Vanhoenacker
Xing-Hong Leng
Rachelle Mutch

Institutions

Thermo Fisher Scientific (Sweden) (SE)
Argenx (Belgium) (BE)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000212107
Primary Topic: Muscle Physiology and Disorders
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

First-in-Human Dose Selection and Pharmacokinetics, Safety, Tolerability, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase (P10-2.007)

Tonke Van Bragt, Samir Patel, Roeland Vanhauwaert, Christa Kneip et al.

Apr 7, 2025

Neurology

Muscle Physiology and Disorders

article

First-in-Human Dose Selection and Pharmacokinetics, Safety, Tolerability, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase (P10-2.007)

Tonke Van Bragt, Samir Patel, Roeland Vanhauwaert, Christa Kneip, Sofie Priem, Rebecca A. Shilling, Cristina Vaghi, Peter Vanhoenacker, Xing-Hong Leng, Rachelle Mutch

April 7, 2025article en

Abstract

To present the approach for selection of first-in-human (FIH) doses and the results of a phase 1, FIH, double-blinded, placebo-controlled study (NCT05670704) of single ascending doses (SAD) and multiple ascending doses (MAD) of ARGX-119 in healthy participants.

NeurologyVol. 104(7_Supplement_1)

Thermo Fisher Scientific (Sweden) (SE), Argenx (Belgium) (BE)

Good health and well-being

Openalex Percentile: Top 94%

Muscle Physiology and Disorders

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.